布局运动医学领域 爱博医疗计划收购德美医疗68.31%股权

Core Viewpoint - Aibo Medical plans to acquire a 68.31% stake in Demei Medical for a transaction price of 683 million yuan, utilizing merger loans and its own funds [1][2]. Group 1: Acquisition Details - The acquisition aims to enhance Aibo Medical's presence in the healthcare sector, particularly in the research, production, and sales of medical devices [2]. - Demei Medical is a leading company in sports medicine, with its main revenue source being sports medicine implants, accounting for approximately 80% of its total revenue [1][2]. Group 2: Financial Impact - Demei Medical's projected revenue for 2025 is 286 million yuan, with an adjusted net profit of 23.6 million yuan [2]. - The acquisition will involve a cash payment, leading to a significant cash outflow for Aibo Medical, with 70%-80% of the transaction price expected to be financed through bank loans [2]. - Aibo Medical plans to use its own funds to repay the loan principal and interest in installments, which may result in increased financial expenses and impact the company's profits [2].